- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Involvement of innate immunity in the expansion of multiple myeloma cells and therapeutic intervention with lenalidomide
-
- FURUKAWA Yusuke
- Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University
-
- KURODA Yoshiaki
- Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University
-
- KIKUCHI Jiro
- Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University
Bibliographic Information
- Other Title
-
- 多発性骨髄腫の増殖における自然免疫の関与とlenalidomideによる介入
- タハツセイ コツズイシュ ノ ゾウショク ニ オケル シゼン メンエキ ノ カンヨ ト lenalidomide ニ ヨル カイニュウ
Search this article
Description
<p>Multiple myeloma (MM) cells acquire dormancy and drug resistance via their interaction with bone marrow stroma cells (BMSCs) in a hypoxic microenvironment. In this study, we found a positive expression of CD180/MD-1 complex (a non-canonical toll-like receptor) on MM cells, which was markedly up-regulated under adherent and/or hypoxic conditions. Bacterial lipopolysaccharide (LPS) enhanced the growth of MM cells via the activation of MAP kinases, an effect which showed a positive correlation with the expression levels of CD180. LPS administration significantly increased CD180/CD138 double-positive cell number in a murine xenograft model after the inoculation of MM cells directly attached to BMSCs. Notably, the shRNA-mediated knockdown of CD180 terminated the LPS response in vitro and in vivo. Promoter analyses identified IKZF1 (Ikaros) as a pivotal transcriptional activator of the CD180 gene, whose transcription was activated via cell adhesion and hypoxia by increasing Ikaros expression and its binding to the promoter region. Pharmacological targeting of Ikaros with lenalidomide ameliorated the response of MM cells to LPS in a CD180-dependent manner in vitro and in vivo. CD180/MD-1 pathway may represent a novel mechanism for the regulation of the growth of MM cells in BM milieu and may serve as a therapeutic target to prevent the regrowth of dormant MM cells.</p>
Journal
-
- Rinsho Ketsueki
-
Rinsho Ketsueki 59 (8), 1048-1057, 2018
The Japanese Society of Hematology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001288066696192
-
- NII Article ID
- 130007472200
-
- NII Book ID
- AN00252940
-
- ISSN
- 18820824
- 04851439
-
- NDL BIB ID
- 029225744
-
- PubMed
- 30185705
-
- Text Lang
- ja
-
- Article Type
- journal article
-
- Data Source
-
- JaLC
- NDL Search
- PubMed
- CiNii Articles
- KAKEN
- OpenAIRE
-
- Abstract License Flag
- Disallowed